{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:44:36Z","timestamp":1761101076922},"reference-count":123,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/cco.0b013e32834bb88e","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T23:56:09Z","timestamp":1317772569000},"page":"681-691","source":"Crossref","is-referenced-by-count":9,"title":["Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma"],"prefix":"10.1097","volume":"23","author":[{"given":"Koen","family":"van Besien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210128","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.","volume":"77","author":"Jones","year":"1991","journal-title":"Blood"},{"key":"R2-20-20210128","first-page":"483","article-title":"High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.","volume":"4","author":"Petersen","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"R3-20-20210128","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1987.5.9.1340","article-title":"Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation.","volume":"5","author":"Appelbaum","year":"1987","journal-title":"J Clin Oncol"},{"key":"R4-20-20210128","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","article-title":"Autologous versus allogeneic bone marrow transplantation for non-Hodgkins lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group registry data.","volume":"10","author":"Chopra","year":"1992","journal-title":"J Clin Oncol"},{"key":"R5-20-20210128","first-page":"353","article-title":"Bone marrow transplantation in 46 pediatric patients with non-Hodgkins lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children.","volume":"15","author":"Bureo","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"R6-20-20210128","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkins lymphoma.","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"R7-20-20210128","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bmt.1702625","article-title":"Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkins lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.","volume":"26","author":"Schimmer","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R8-20-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R9-20-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R10-20-20210128","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","article-title":"Performance status and comorbidity predict transplant related mortality after allogeneic hematopoietic cell transplantation.","volume":"12","author":"Artz","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R11-20-20210128","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"R12-20-20210128","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation.","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-20-20210128","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effects.","volume":"19","author":"Van Besien","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R14-20-20210128","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/10428190290017051","article-title":"Graft versus Burkitts lymphoma effect after allogeneic marrow transplantation.","volume":"43","author":"Grigg","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R15-20-20210128","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI First International Workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.","volume":"16","author":"Porter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-20-20210128","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bbmt.2004.05.008","article-title":"Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology.","volume":"9","author":"Grigg","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"R17-20-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2141.1999.01666.x","article-title":"Allogeneic bone marrow transplantation in aggressive non-Hodgkins lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle.","volume":"107","author":"Dhedin","year":"1999","journal-title":"Br J Haematol"},{"key":"R18-20-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.1996.14.1.214","article-title":"Outcome of high-dose therapy and autologous transplantation in non-Hodgkins lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest.","volume":"14","author":"Sharp","year":"1996","journal-title":"J Clin Oncol"},{"key":"R19-20-20210128","first-page":"3753","article-title":"Syngeneic hematopoietic stem cell transplantation for non-Hodgkins lymphoma: a comparison with allogeneic and autologous transplantation.","volume":"3744-","author":"Bierman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R20-20-20210128","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.1999.01337.x","article-title":"A history of haemopoietic cell transplantation.","volume":"105","author":"Thomas","year":"1999","journal-title":"Br J Haematol"},{"key":"R21-20-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","article-title":"Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and nonmethotrexate-containing graft-versus-host disease prophylaxis regimens.","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"R22-20-20210128","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.1986.4.4.480","article-title":"High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma.","volume":"4","author":"Phillips","year":"1986","journal-title":"J Clin Oncol"},{"key":"R23-20-20210128","first-page":"653","article-title":"Transplantation conditioning regimens: can we say it better Biol Blood Marrow T","volume":"15","author":"Deeg","year":"2009","journal-title":"ransplant"},{"key":"R24-20-20210128","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R25-20-20210128","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions.","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R26-20-20210128","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood-2005-02-0596","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan.","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"R27-20-20210128","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"R28-20-20210128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2008.02.014","article-title":"Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation.","volume":"14","author":"Tomblyn","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R29-20-20210128","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkins lymphoma.","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R30-20-20210128","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2010-12-324392","article-title":"90Y-ibritumomab tiuxetan, fludarabine, and TBI based nonmyeloablative allogeneic transplant conditioning for patients with persistent high-risk B-cell lymphoma.","volume":"118","author":"Gopal","year":"2011","journal-title":"Blood"},{"key":"R31-20-20210128","first-page":"150","article-title":"Allogeneic transplantation for recurrent or refractory non-Hodgkins lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, cyclophosphamide. Experience in 44 consecutive patients.","volume":"3","author":"van Besien","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"key":"R32-20-20210128","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bbmt.2006.05.018","article-title":"Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkins lymphoma.","volume":"12","author":"Aksentijevich","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R33-20-20210128","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-010-0747-x","article-title":"Targeted IV busulfan and fludarabine followed by postallogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20 lymphoid malignancies without increased risk of infectious complications.","volume":"93","author":"Pidala","year":"2011","journal-title":"Int J Hematol"},{"key":"R35-20-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a010369","article-title":"Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for hig-risk malignant lymphoma.","volume":"10","author":"Przepiorka","year":"1999","journal-title":"Ann Oncol"},{"key":"R36-20-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","article-title":"BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.","volume":"103","author":"Faulkner","year":"2004","journal-title":"Blood"},{"key":"R37-20-20210128","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bbmt.2006.02.009","article-title":"High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.","volume":"12","author":"Law","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R38-20-20210128","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkins lymphoma.","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"key":"R39-20-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/10428194.2010.538777","article-title":"T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed lymphoma. Predictors for survival after transplant relapse.","volume":"52","author":"Kenkre","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R40-20-20210128","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","article-title":"Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.","volume":"23","author":"Baron","year":"2005","journal-title":"J Clin Oncol"},{"key":"R41-20-20210128","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"key":"R42-20-20210128","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2010.210","article-title":"Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.","volume":"24","author":"Baker","year":"2010","journal-title":"Leukemia"},{"key":"R43-20-20210128","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","article-title":"Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.","volume":"12","author":"Bacigalupo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R44-20-20210128","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"key":"R45-20-20210128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbmt.2006.09.004","article-title":"Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies.","volume":"13","author":"Novitzky","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R46-20-20210128","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.bmt.1701209","article-title":"T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkins lymphoma: clinical and molecular follow-up.","volume":"21","author":"Juckett","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R47-20-20210128","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/bmt.2009.371","article-title":"Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.","volume":"45","author":"Perales","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"R48-20-20210128","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.","volume":"100","author":"Perez-Simon","year":"2002","journal-title":"Blood"},{"key":"R49-20-20210128","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bmt.1704600","article-title":"Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect.","volume":"34","author":"Glass","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R50-20-20210128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1705249","article-title":"Pretransplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.","volume":"37","author":"Kline","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R51-20-20210128","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbmt.2003.11.001","article-title":"Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.","volume":"10","author":"Avivi","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"R52-20-20210128","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"R53-20-20210128","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","article-title":"Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.","volume":"26","author":"Armand","year":"2008","journal-title":"J Clin Oncol"},{"key":"R54-20-20210128","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","article-title":"Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).","volume":"109","author":"Estey","year":"2007","journal-title":"Blood"},{"key":"R55-20-20210128","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2141.2007.06862.x","article-title":"Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.","volume":"139","author":"Hardy","year":"2007","journal-title":"Brit J Haematol"},{"key":"R56-20-20210128","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood.V116.21.2709.2709","article-title":"Pre-donor evaluation of an HLA matched sibling identifies a novel inherited RUNX1 mutation encoding a missense mutation found outside of the RUNT domain in familial platelet disorder (ASH Annual Meeting Abstracts).","volume":"116","author":"Garcia","year":"2010","journal-title":"Blood"},{"key":"R57-20-20210128","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"R58-20-20210128","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R59-20-20210128","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/leu.2009.1","article-title":"The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or nonmyeloablative allogeneic stem cell transplantation.","volume":"23","author":"Farina","year":"2009","journal-title":"Leukemia"},{"key":"R60-20-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","article-title":"Nonmyeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.","volume":"143","author":"Rezvani","year":"2008","journal-title":"Br J Haematol"},{"key":"R61-20-20210128","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.bbmt.2010.12.702","article-title":"Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.","volume":"17","author":"Ho","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R62-20-20210128","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbmt.2008.06.005","article-title":"Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.","volume":"14","author":"Dew","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R63-20-20210128","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R64-20-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bbmt.2008.11.013","article-title":"Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.","volume":"15","author":"Brunstein","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R65-20-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"R66-20-20210128","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"R67-20-20210128","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"R68-20-20210128","first-page":"5684","article-title":"TBC (thiotepa, busulfan, cyclophosphamide) conditioning for second autologous transplants in patients with primary mediastinal B cell lymphoma may induce durable remissions abstract.","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"R69-20-20210128","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2001.19.6.1855","article-title":"Primary mediastinal B-cell lymphoma: a review of pathology and management.","volume":"19","author":"van Besien","year":"2001","journal-title":"J Clin Oncol"},{"key":"R70-20-20210128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.1998.16.1.63","article-title":"High dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma; mediastinal localization predicts for a favorable outcome.","volume":"16","author":"Popat","year":"1998","journal-title":"J Clin Oncol"},{"key":"R71-20-20210128","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkins lymphoma.","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"R72-20-20210128","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"R73-20-20210128","first-page":"47","article-title":"Allogeneic marrow transplantation in non-Hodgkins lymphoma.","volume":"5","author":"Copelan","year":"1990","journal-title":"Bone Marrow Transplant"},{"key":"R74-20-20210128","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1200\/JCO.1991.9.10.1848","article-title":"Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors.","volume":"9","author":"Lundberg","year":"1991","journal-title":"J Clin Oncol"},{"key":"R75-20-20210128","first-page":"81","article-title":"Marrow transplantation for non-Hodgkins lymphoma: a multicentre study from the European co-operative bone marrow transplant group.","volume":"1","author":"Ernst","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"R76-20-20210128","first-page":"591","article-title":"Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkins lymphoma.","volume":"12","author":"Shepherd","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"R77-20-20210128","first-page":"299","article-title":"Allogeneic bone marrow transplantation for Hodgkins and non Hodgkins lymphoma.","volume":"95","author":"Mendoza","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"R78-20-20210128","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0360-3016(95)00115-F","article-title":"Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase III trial.","volume":"95","author":"Demirer","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R79-20-20210128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.1995.13.3.596","article-title":"High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.","volume":"95","author":"Demirer","year":"1995","journal-title":"J Clin Oncol"},{"key":"R80-20-20210128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.bmt.1700904","article-title":"Allogeneic bone marrow transplantation for relapsed and refractory Hodgkins disease and non-Hodgkins lymphoma.","volume":"20","author":"Dann","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R81-20-20210128","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R82-20-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","article-title":"Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.","volume":"131","author":"Doocey","year":"2005","journal-title":"Br J Haematol"},{"key":"R83-20-20210128","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2009-11-255182","article-title":"Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.","volume":"115","author":"Lambert","year":"2010","journal-title":"Blood"},{"key":"R84-20-20210128","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1002\/cncr.25357","article-title":"Pretransplantation 18-Ffluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation.","volume":"116","author":"Dodero","year":"2010","journal-title":"Cancer"},{"key":"R85-20-20210128","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cncr.24845","article-title":"Correlation of pretransplant and early posttransplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkins lymphoma.","volume":"116","author":"Bishop","year":"2010","journal-title":"Cancer"},{"key":"R86-20-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bbmt.2005.04.005","article-title":"Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory nonhodgkin lymphoma.","volume":"11","author":"Dean","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"R87-20-20210128","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2004-01-0231","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation in patients who relapse after autologous stem cell transplantation for lymphoma: a report of the international bone marrow transplant registry.","volume":"104","author":"Freytes","year":"2004","journal-title":"Blood"},{"key":"R88-20-20210128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bbmt.2010.07.015","article-title":"Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multiinstitutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).","volume":"17","author":"Bashey","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R90-20-20210128","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1200\/JCO.2004.09.092","article-title":"Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkins lymphoma whose disease has failed a prior autologous transplantation.","volume":"22","author":"Escalon","year":"2004","journal-title":"J Clin Oncol"},{"key":"R91-20-20210128","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkins lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"R92-20-20210128","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2006.06.9914","article-title":"Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.","volume":"24","author":"Baron","year":"2006","journal-title":"J Clin Oncol"},{"key":"R93-20-20210128","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bbmt.2008.05.021","article-title":"Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.","volume":"14","author":"Smith","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R94-20-20210128","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"R95-20-20210128","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(97)89488-0","article-title":"Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.","volume":"100","author":"Van Besien","year":"1996","journal-title":"Am J Med"},{"key":"R96-20-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents.","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R97-20-20210128","first-page":"1","article-title":"Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.","volume":"8","author":"Armitage","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"R98-20-20210128","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.","volume":"23","author":"Molina","year":"2005","journal-title":"J Clin Oncol"},{"key":"R99-20-20210128","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"key":"R100-20-20210128","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and nonmyeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"key":"R101-20-20210128","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/sj.bmt.1704897","article-title":"Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma.","volume":"35","author":"Mansour","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R102-20-20210128","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome.","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R103-20-20210128","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"key":"R104-20-20210128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","article-title":"Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Munster group report.","volume":"133","author":"Woessmann","year":"2006","journal-title":"Br J Haematol"},{"key":"R105-20-20210128","first-page":"961","article-title":"Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma.","volume":"116","author":"Shustov","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"R106-20-20210128","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkins lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"R107-20-20210128","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2011.574754","article-title":"Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.","volume":"52","author":"Zain","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R108-20-20210128","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","article-title":"Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.","volume":"150","author":"Shustov","year":"2010","journal-title":"Br J Haematol"},{"key":"R109-20-20210128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1705036","article-title":"Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkins lymphoma.","volume":"36","author":"Wulf","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R110-20-20210128","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"R111-20-20210128","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bbmt.2007.10.019","article-title":"Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.","volume":"14","author":"Dreger","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R112-20-20210128","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoidesSezary syndrome.","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"key":"R113-20-20210128","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12185-010-0724-4","article-title":"Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia.","volume":"92","author":"Kwong","year":"2010","journal-title":"Int J Hematol"},{"key":"R114-20-20210128","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3109\/10428194.2010.487958","article-title":"Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killerT cell lymphoma, nasal type.","volume":"51","author":"Yokoyama","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R115-20-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"key":"R116-20-20210128","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/10428194.2011.572322","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killerT-cell lymphoma, nasal type.","volume":"52","author":"Ennishi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R118-20-20210128","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbmt.2006.09.002","article-title":"Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemialymphoma: retrospective analysis of data from the Japan Marrow Donor Program.","volume":"13","author":"Kato","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R119-20-20210128","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbmt.2008.04.014","article-title":"A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemialymphoma (ATL): clinical impact of graft-versus-leukemialymphoma effect.","volume":"14","author":"Shiratori","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R120-20-20210128","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"key":"R123-20-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.","volume":"36","author":"Russell","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R124-20-20210128","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkins lymphoma (NHL).","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"R125-20-20210128","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3109\/10428190903200790","article-title":"Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.","volume":"50","author":"van Besien","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R126-20-20210128","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/10428190903275594","article-title":"Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation.","volume":"51","author":"Cavattoni","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R127-20-20210128","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.bbmt.2010.05.004","article-title":"Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.","volume":"16","author":"McIver","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R128-20-20210128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbmt.2010.07.008","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review.","volume":"17","author":"Oliansky","year":"2011","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32834bb88e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T08:09:43Z","timestamp":1712995783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201111000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32834bb88e","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}